News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

US Patent Covering Amplification Consumables Granted to Enigma Diagnostics


4/19/2010 9:54:19 AM

OXFORD, England and SAN DIEGO, April 19 /PRNewswire/ -- Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 7,659,096 with claims that cover the use of amplification consumables in several current real-time and end point PCR instruments. The consumables incorporate a thermally conducting layer and reaction wells in combination with a reaction mixture and a blocking agent. Enigma Diagnostics Ltd is the exclusive licensee of this patent from the UK Defence Science Technology Laboratory.

Enigma Diagnostics Limited specialises in developing next generation rapid molecular diagnostic instrument platforms for decentralized and point-of-care settings.

Enigma has an exclusive license from the Defence Science Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded Research. It also has licences from Applied Biosystems and Celera Diagnostics for commercialisation of real-time PCR instruments, and from Roche Molecular Systems to practise HybProbe real-time PCR chemistry for human and veterinary in vitro diagnostics. Enigma's in-house RandD activities have generated a portfolio of worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including US, EU and Japan with more extensive filing and grants across a number of other key territories.

Enigma Diagnostics Limited





Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES